Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Shares Outstanding (Diluted Average) (2019 - 2023)

CytomX Therapeutics' Shares Outstanding (Diluted Average) history spans 5 years, with the latest figure at $73.8 million for Q4 2023.

  • For Q4 2023, Shares Outstanding (Diluted Average) rose 12.27% year-over-year to $73.8 million; the TTM value through Dec 2023 reached $73.8 million, up 12.27%, while the annual FY2023 figure was $73.8 million, 12.27% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $73.8 million in Q4 2023 per CTMX's latest filing, up from $66.5 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $73.8 million in Q4 2023 to a low of $45.3 million in Q4 2019.
  • Average Shares Outstanding (Diluted Average) over 5 years is $59.7 million, with a median of $65.1 million recorded in 2021.
  • Peak YoY movement for Shares Outstanding (Diluted Average): skyrocketed 41.78% in 2021, then rose 0.63% in 2022.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $45.3 million in 2019, then increased by 1.79% to $46.1 million in 2020, then soared by 39.01% to $64.1 million in 2021, then grew by 2.48% to $65.7 million in 2022, then increased by 12.27% to $73.8 million in 2023.
  • Per Business Quant, the three most recent readings for CTMX's Shares Outstanding (Diluted Average) are $73.8 million (Q4 2023), $66.5 million (Q2 2023), and $66.2 million (Q1 2023).